Novavax (NVAX) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Novavax (NVAX) is Neutral.

The composite score behind that read is +0.06, weighing +0.18 of bullish evidence against -0.23 bearish.

Novavax last closed at $12.75, +15.80% on the session.

Against the IVW growth benchmark the position is +15.00% over the forecast window.

The read is built from 15 underlying insights — 2 bullish and 13 bearish.

Agreement across those insights is 87%.

15 graded predictions for NVAX so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Novavax in the 97th percentile on return on equity, where 100 is best.

Novavax is classified under Health Care / Biotechnology, with a market capitalisation of $1.82B.

StockMap tracks Novavax as the 97th largest of the 381 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 301 Neutral, 63 Moderate Underperform and 17 Moderate Outperform.

On that composite Novavax ranks 61st of 381 in the group, against a group median of -0.08.